Key Takeaways
- Chemicals margin hit masks pharma progress: A ~40% acetic acid price crash left the company with high-cost inventory, compressing chemicals margins, while the API business quietly reached double-digit EBITDA and guided to 15% by year-end.
- Recovery is a Q3/Q4 story, not Q2: High-cost raw material inventory is now exhausted; management expects both chemicals profitability and API margin improvement to materialize in the second half.
- Capex signals conviction, not caution: The company spent more on capex this year than any prior year, much of it on EHS and warehousing that does not directly generate revenue, which management calls as strong an indicator of confidence as a buyback.
- FY23 muted, FY24 double-digit: Single-digit revenue growth this year gives way to a confident double-digit growth outlook for FY24, driven by capacity expansions coming online by year-end.
- What to watch next quarter: Whether the promised margin recovery actually shows up in both segments, the pace of ethyl acetate capacity commissioning, and any progress on the west-side expansion site selection.
Chemicals Segment: The Inventory Overhang
- Ethyl acetate price drove the revenue dip: Chemicals revenue depends entirely on ethyl acetate pricing because volume is capped until capacity expansion comes online; the price corrected ~14% QoQ, causing the segment decline.
- Raw material timing mismatch is the core problem: Acetic acid, the key raw material, saw prices fall ~40% over a period of weeks, not months. The company purchases months in advance, so it was stuck with high-cost inventory while finished product prices fell, a margin squeeze that is structural to the spot nature of the chemicals business.
- No domestic acetic acid supply compounds the risk: Management noted that if acetic acid were manufactured domestically in India, ethyl acetate makers would not face this sourcing and timing challenge at all.
- Inventory overhang now cleared: The high-value raw material inventory is exhausted; profitability is expected to return in Q3 and Q4.
- Long-term customer relationships override quarterly margin pressure: Management will not stop production or walk away from a decade-long customer just because one quarter is unprofitable, framing the chemicals business as part of a broader relationship that includes API sales.
Dr. Sanjay Chaturvedi: "Believe me, if acetic acid was available domestically through manufacturers in India, none of the ethyl acetate manufacturers would be facing this issue."
Pharmaceuticals Segment: Building the Quality Mix
- API business already at double-digit EBITDA: The pharmaceutical segment grew on volume and asset utilization, with the API business delivering double-digit EBITDA margins this quarter despite a muted industry environment where almost all peers de-grew profits QoQ.
- 15% EBITDA target by year-end: Management set a clear baseline: running an API business at about 15% EBITDA margin is a reasonably good quality business, and the company expects to get there by the end of this fiscal year.
- Non-ibuprofen portfolio to overtake ibuprofen within 2 years: The non-ibuprofen portfolio is expected to exceed ibuprofen revenues in the next two years, driven by products like metformin, paracetamol, and clopidogrel shifting toward regulated markets.
- Asset utilization unlocks profitability: Non-ibuprofen margins are not yet translating because overall asset utilization must cross ~60–65% before profit churn starts; the first objective is high utilization via low-margin domestic business, then parlay volume into higher-margin regulated markets.
- Ibuprofen running at ~80% utilization: Current output is ~800 tonnes per month; the near-term target is 85% utilization with no capacity addition planned, focusing instead on improving run rate.
- Metformin strategy is quality over quantity: No capacity addition planned; the strategy is to shift the customer mix toward regulated markets (US and Europe) where price realization is higher, rather than selling more volume.
- Paracetamol fully backward integrated: The company makes its own PAP (para-aminophenol) and manufactures paracetamol from captive PAP; all quality issues are ironed out, and regulatory filings for US and Europe approvals are underway, so this will not be a low-margin business.
Dr. Sanjay Chaturvedi: "I would say in the next 2 years, one should expect that the non-ibuprofen portfolio will exceed the revenues from the ibuprofen portfolio."
Capacity Expansion & Capex
- Record capex year, much of it non-revenue: The company spent more on capex this year than any prior year, with a significant portion directed to EHS (environment, health, safety) and warehousing, investments that do not translate directly into revenue but signal long-term commitment.
- New capacities by year-end: Capacity expansions for both specialty chemicals and pharma products are in process and should come online by the end of this financial year, with revenue accruals starting in Q1 of next financial year.
- Ethyl acetate expansion: The new plant should be up and running by year-end; 70–80% of the expanded capacity is expected to be absorbed domestically, with the balance going to regular export customers.
- Chemicals top line to grow ~20% next year: With the 20% capacity expansion, chemicals segment revenue is expected to be roughly 20% higher in FY24.
- West-side expansion still in site selection: The company has contracted credible partners to identify a site for a west-side expansion; a conclusion on what and at what scale may come by Q4.
Dr. Sanjay Chaturvedi: "This is actually a year I would argue that we spent more on Capex than any other year. And in fact, a lot of the Capex spend that we have done has gone into things like EHS to take care of the environment, and into warehousing. These are investments into Capex that don't necessarily translate directly into revenue. But to me, they are as strong of an indicator as a buyback program."
Regulatory & Market Access Progress
- REACH certificate opens EU for ethyl acetate: The company received REACH certification with a tonnage band of more than 1,000 tonnes per annum, allowing ethyl acetate exports across all EU countries, though near-term exports are unattractive due to a Chinese price crash.
- EDQM certification for pantoprazole sodium: Received certification to supply pantoprazole sodium as an API in European markets, adding to the regulated-market product portfolio.
- Regulatory filings accelerating: The company has increased filings from ~1 product per year historically to at least 4 products per year since last year, with a steady-state target of 5–6 product filings per year.
- USFDA platform ready: Plants are already USFDA approved; DMFs have been filed for a couple of products, and the company continues to file more DMFs along with CEP approvals.
- Sitagliptin process patent granted: The Indian patent office granted a process patent for a novel, greener process providing a cost advantage; the product is still under development and validation, with launch a few quarters out.
- China-plus-one tailwind: Supply disruptions from COVID-related lockdowns in China are opening opportunities for Indian API players, a situation management expects to persist over the next few quarters.
Segment Economics & Margin Structure
- Chemicals is a spot business with thin structural margins: The chemicals side is a very spot business; on average, management expects EBITDA margins in the 6–8% range consistently, while the real money in APIs comes from exporting into regulated markets.
- API margin improvement is a mix-shift story: The path to higher API margins runs through shifting volume from low-margin domestic business to higher-margin regulated markets as asset utilization crosses critical thresholds.
- Power costs a broad industry drag: QoQ margins declined for almost all pure-play API players, with power costs playing a significant role as power prices rose in India.
- Ibuprofen profitability softened: Some fall in ibuprofen profitability occurred due to price decreases, though the product remains a volume anchor at ~80% utilization.
- Raw material pass-through works in pharma, not in chemicals: On the pharmaceuticals side, raw material price increases have been passed along, but in commodity chemicals it is not easily possible to pass on the entire cost increase.
Dr. Sanjay Chaturvedi: "I think it is good to understand what the baseline is, and I would say that running an API business at about 15% EBITDA margin is a reasonably good quality business and we will get there by the end of this year."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Double-digit EBITDA margins | Company-wide return to double-digit EBITDA | Next 2 quarters |
| API EBITDA margin | Reach ~15% EBITDA margin | By end of this fiscal year |
| FY23 revenue growth | Muted, single-digit growth | Current fiscal year |
| FY24 revenue growth | Double-digit top line growth (value, not just volume) | Next financial year |
| Capacity expansion online | New specialty chemicals and pharma capacities operational | By end of this financial year |
| Chemicals top line growth | ~20% higher top line from chemicals segment | Next financial year |
| Ibuprofen utilization | Take asset utilization to ~85% | Next few quarters |
| Non-ibuprofen portfolio | Exceed ibuprofen revenues | Within 2 years |
| Regulatory filings | Steady state of 5–6 product filings per year | Ongoing from current elevated rate |
| Ethyl acetate capacity absorption | 70–80% of expanded capacity absorbed domestically | Once expansion is online |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Revenue growth guidance | Single-digit growth for FY23; double-digit growth expected for next financial year |
| EBITDA margin | Below double-digit; management expects return to double-digit margins in next 2 quarters |
| API business EBITDA margin | Double-digit in Q2; target of about 15% by end of FY23 |
| Chemicals business EBITDA margin | 6% to 8% sustainable range on average |
| PAT decline | 55% down (per an analyst's math, stated by an investor, not confirmed by management) |
| Pharma segment revenue | ₹250–300 crore per quarter range over last 3–4 years |
| Non-ibuprofen portfolio revenue | ~₹500 crore in FY23; expected to exceed ibuprofen revenues in next 2 years |
| Non-ibuprofen business H1 revenue | ₹240 crore |
| Non-ibuprofen asset utilization | ~50% plus/minus; some plants at 70%, some below 50% |
| Ibuprofen capacity utilization | 75% to 80%; target of about 85% in next few quarters |
| Ibuprofen monthly run rate | ~800 tonnes per month, roughly 80% of capacity |
| Ibuprofen export price | $11 to $12 per kg; slightly lower for Indian market, pricing stable |
| Ibuprofen global market share | ~33% of world capacity; upwards of 50% including intermediates supplied to other manufacturers |
| Metformin asset utilization | Above 90% |
| Metformin export share | ~10% of volume; rest domestic |
| Ethyl acetate price change | ~14% decline Q1 to Q2 |
| Acetic acid price change | ~40% decline Q1 to Q2; roughly 40% YoY |
| Ethyl acetate exports | ~20% of production |
| Ethyl acetate capacity expansion | 20,000 tonnes per year; expected online by end of FY23, accruals from Q1 FY24 |
| Capex guidance | ₹100–150 crore per annum |
| Total import dependence | ~40% of total consumption; chemicals side ~70%, pharma side 15–20% excluding DCDA |
| Intersegment transfers | ~₹115 crore in H1 FY23; expected ~₹150 crore plus/minus per year |